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Pemphigus is a blistering disease characterized by pemphigus autoantibodies (PVIgG) 
directed mostly against desmogleins (Dsgs), resulting in the loss of keratinocyte adhe-
sion (acantholysis). Yet, the mechanisms underlying blister formation remain to be 
clarified. We have shown previously that anti-Fas ligand (FasL) antibody (Ab) prevents 
PVIgG-induced caspase-8 activation and Dsg cleavage in human keratinocytes, and 
that sera from pemphigus patients contain abnormally increased levels of FasL. Here, 
we demonstrate that recombinant FasL induces the activation of caspases prior to Dsg 
degradation, and anti-FasL Ab prevents acantholysis in cultured keratinocytes. Moreover, 
the silencing of FasL reduces PVIgG-induced caspase-8 activation and Dsg3 cleavage. 
Following injection of PVIgG into mice, FasL is upregulated at 1–3 h and is followed by 
caspase-8-mediated keratinocyte apoptosis, before blister formation. The administration 
of anti-FasL Ab after PVIgG injection blocks blister formation in mice. Furthermore, we 
injected PVIgG into two different gene-targeted mutant mice that selectively lack either 
secreted soluble FasL (sFasL), FasLΔs/Δs mice, or the membrane-bound form of FasL 
(mFasL), FasLΔm/Δm mice. After PVIgG treatment, blisters are only visible in FasLΔm/Δm ani-
mals, lacking mFasL, but still producing sFasL, similar to wild-type (C57BL/6) animals. 
By contrast, a significant decrease in the relative acantholytic area is observed in the 
FasLΔs/Δs animals. These results demonstrate that soluble FasL plays a crucial role in the 
mechanisms of blister formation, and blockade of FasL could be an effective therapeutic 
approach for pemphigus.
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inTrODUcTiOn
Pemphigus is a rare and potentially lethal autoimmune skin disease, characterized by the loss of 
keratinocyte adhesion at the level of desmosomes, a phenomenon known as acantholysis. This 
results in the formation of flaccid blisters and/or erosions in both skin and mucous membranes 
(1). Pathogenic autoantibodies [pemphigus autoantibodies (PVIgG)] in sera from pemphigus 
patients target predominantly molecular components of the desmosomes, such as desmoglein 
(Dsg)3 [pemphigus vulgaris (PV)] and Dsg1 [pemphigus foliaceous (PF)] [reviewed by Stanley and 
Amagai (2)]. Although autoantibodies play an essential role in the pathogenesis of pemphigus (3), 
the mechanisms leading to the formation of the blisters remain largely unknown (4, 5). Several 
lines of evidence indicate that apoptosis is involved in the pathological mechanisms of pemphigus 
[reviewed by Grando et al., (6)]. In particular, cleaved caspase-8 and -3 are detected in pemphigus 
lesions, and caspase-8-positive cells express Fas ligand (FasL)/Fas binding (7, 8).
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Fas Ligand is a transmembrane protein (mFasL) that can be 
proteolytically cleaved to generate its soluble form of 26  kDa 
(sFasL) (9). Both forms of FasL can bind to their receptor, Fas, 
also known as CD95 or Apo1. The membrane-bound form 
triggers the extrinsic apoptotic pathway through the activation 
of caspase-8 (10), while the soluble form appears to have both 
apoptotic and pro-inflammatory activities in immune cells 
(11, 12). In healthy skin, FasL is localized in the basal layer and in 
the first suprabasal layers of the epidermis, homogeneously dis-
tributed within the cytoplasm, in association with intermediate 
filaments (13). PVIgG upregulate FasL at the mRNA and protein 
level in human keratinocytes (14). We have shown previously 
that anti-FasL antibodies (Ab) prevent PVIgG-induced caspase-8 
activation and Dsg cleavage in human keratinocytes (6) and that 
sera from pemphigus patients contain abnormally increased 
levels of FasL (15).
In this study, we demonstrate that the inhibition of FasL 
prevents apoptosis and acantholysis in  vitro, and anti-FasL Ab 
blocks blister formation in vivo. Finally, using two mutant mice 
selectively lacking the sFasL or mFasL, we provide evidence that 
sFasL plays a critical role in blister formation in pemphigus.
MaTerials anD MeThODs
Pemphigus samples
Biopsies (4-mm punch) from lesional and perilesional pemphi-
gus skin as well as from normal skin of healthy volunteers were 
obtained from the Institute of Dermatology, at the University of 
Modena and Reggio Emilia. Samples were embedded in OCT 
and frozen at −20°C. In all patients, diagnosis was based on (1) 
typical skin and/or mucous membrane lesions, (2) detection of 
circulating autoantibodies by indirect immunofluorescence on 
monkey esophagus (a titer of 1:320), and (3) reactivity to Dsgs 
in patients’ sera by ELISA (MBL International Corp., Nagoya, 
Japan). Sera were collected from patients with PV, mucocutane-
ous pemphigus, and PF and pooled for IgG purification (Dsg1: 
106.2 U/ml; Dsg3: 158.2 U/ml). Sera were also collected from 
healthy volunteers (Dsg1: 2.6 U/ml; Dsg3: 3.2 U/ml).
igg Purification
Pemphigus autoantibodies and normal human IgG (NIgG) were 
purified by affinity binding on a HiTrapProtein G HP column (GE 
Healthcare Bio-Science, Piscataway, NJ, USA). Sera were pooled 
and diluted (1:10) in 20 mM phosphate buffer (pH 7) and loaded 
on the column. Bound IgG was eluted with 0.1 M glycine/HCl 
(pH 2.7) and immediately neutralized by Tris 1 M (pH 9). Purified 
IgGs were dialyzed extensively against phosphate-buffered saline 
(PBS) (pH 7.4), concentrated by ultrafiltration (Amicon, Beverly, 
MA, USA), filter-sterilized, and stored at +4°C until use. Protein 
concentration was determined by Bradford assay using protein 
Standard I (BioRad, Hercules, CA, USA).
cell cultures
Normal human keratinocytes were obtained from foreskin and 
cultured as described previously (16). Briefly, normal human 
keratinocytes were amplified on mitomycin C (Sigma-Aldrich, St 
Louis, MO, USA)-treated 3T3 cells and cultivated in Dulbecco’s 
modified Eagle’s medium and Ham’s F12 medium. Subconfluent 
secondary cultures for experiments were plated in a defined 
serum-free medium (KGM, Lonza Walkersville Inc., Walkersville, 
MD, USA). When cells were confluent, Ca2+ concentration 
was increased to 1.8  mM for 24  h, to induce keratinocyte dif-
ferentiation, before the addition of any stimulus. Either human 
recombinant soluble FasL (rFasL) (0.1, 10, or 50 ng/ml, Sigma) or 
PVIgG and NIgG (1.5 mg/ml) were diluted in keratinocyte basal 
medium (Lonza) plus 1.8 mM Ca2+ and cycloheximide (Sigma) 
1 µg/ml, and incubated for a further 72 h. For in vitro inhibitory 
experiments, keratinocyte cultures were pretreated with either 
1 or 15 µg/ml of purified mouse anti-human FasL monoclonal 
Ab (NOK-2; BD Biosciences Pharmingen, San Diego, CA, USA) 
for 1 h, which was also added when medium was provided with 
NIgG, PVIgG, or rFasL.
Passive Transfer Pemphigus Mouse Model
Neonatal C57BL/6NCrl mice (1–2 days old with body weight of 
approximately 1.3 g) were used for IgG passive transfer experi-
ments [modified from Ref. (17)]. C57BL/6NCrl adult mice were 
obtained from Charles River (Calco, Italy) and maintained at the 
Laboratory Animal Facility, University of Modena and Reggio 
Emilia (Modena). Briefly, 5 mg/g/bw of purified PVIgG or NIgG 
in a total volume of maximum 50 µl was administered to neonatal 
mice by a single subcutaneous (s.c.) injection in the dorsal area. 
Twenty hours after IgG injection, animals were sacrificed and 
samples were collected. FasLΔm/Δm and FasLΔs/Δs animals were 
generated as described by O’Reilly et al. (12) and maintained at the 
Walter and Eliza Hall Institute of Medical Research (Melbourne) 
Animal Facility. FasL-mutant mice and their WT littermates 
were treated as described above. Direct immunofluorescence 
with anti-human IgG (Dako, Glostrup, Denmark) was used to 
demonstrate PVIgG deposition at the skin level. For time course 
studies, animals (n = 5) were sacrificed at various time points post 
IgG injection (0, 1, 3, 6, 9, 12, 18, and 24 h). Skin samples of each 
animal were harvested for hematoxylin and eosin (H&E) staining, 
TUNEL assay, and Western blotting. For inhibitory experiments, 
mice were injected s.c. with 40 µg/mouse of purified hamster anti-
mouse CD178 (FasL) monoclonal Ab (MFL3; BD Pharmingen, 
San Jose, CA, USA) in the same dorsal area of PVIgG or NIgG 
(for control) injection, either 1, 2, or 3 h after IgG administration. 
As negative control, we used purified hamster IgG1, κ-Isotype 
control (40 µg/mouse; BD Pharmingen).
ethics statements
For human samples, this study was carried out in accordance with 
the recommendations of the Ethic Committee of the IDI-IRCCS 
(Istituto Dermatopatico dell’Immacolata, Rome) with written 
informed consent from all subjects. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
The protocol was approved by the Ethic Committee of the IDI-
IRCCS (Istituto Dermatopatico dell’Immacolata, Rome).
For WT C57BL/6 mice procedures, this study was carried 
out in accordance with the recommendations of the Ethical 
Committee of the University of Modena and Reggio Emilia and 
was in accordance with the Italian Institute of Health guidelines. 
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The protocol was approved by the Italian Institute of Health. 
Animal studies conducted on FasL-mutant mice at the Walter 
and Eliza Hall Institute were approved by the Institute’s Animal 
Ethics Committee.
immunohistochemistry
Cryosections (4  µm) of skin from healthy donor and from 
pemphigus patients were methanol-fixed and rehydrated in PBS. 
The staining was performed using the UltraVision LP Detection 
System AP Polymer & Fast Red Chromogen assay (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. 
Briefly, slides were treated with Ultra V Block, and samples were 
incubated with mouse anti-CD95/Fas Ab (UB2; Immunotech, 
Marseille, France) for 1 h at room temperature. After washes in 
PBS, Primary Antibody Enhancer (Thermo Fisher Scientific) was 
added for 20 min at room temperature, followed by incubation 
with AP Polymer anti-mouse/rabbit IgG for 30  min at room 
temperature. Slides were stained with Fast Red using Naphthol 
Phosphate as substrate. Samples were analyzed under a conven-
tional optical microscope (Zeiss Axioskope 40).
Fasl sirna Keratinocyte Transfection
About 8  ×  104 cells/well were plated on six-well plates in 
penicillin/streptomycin-free medium. After 24 h, normal human 
keratinocytes were transfected with 40  nM FasL siRNA (siG-
enome SMARTpool) or scrambled RNAi, as control (Dharmacon 
Inc., Lafayette, CO, USA), combined with Lipofectamine 2000 
and Opti-MEM (both from Invitrogen Corporation, Carlsbad, 
CA, USA), according to manufacturer’s indications. Cells were 
transfected twice and used for PVIgG experiments. FasL protein 
levels were detected by Western blotting, as described below.
Western Blotting
Cells were washed with PBS and lysed on ice in RIPA buffer 
(pH 7.5) containing protease inhibitors (Complete Mini Tablets, 
Roche). Total protein of 40 µg was analyzed on polyacrylamide 
gels and blotted onto nitrocellulose membranes. Blots were 
blocked for 2 h in a blocking buffer (5% nonfat milk in PBS/0.2% 
Tween20, Sigma) and incubated overnight at 4°C with the follow-
ing primary Ab: anti-Dsg3 (5H10; Santa Cruz Biotechnology), 
anti-caspase-8 (Ab-3; Calbiochem, Darmstadt, Germany), 
anti-FasL (Abcam, Cambridge, UK), or anti-β-actin Ab (AC-15; 
Sigma). Membranes were washed in PBS/Tween, incubated with 
HRP-conjugated goat anti-mouse Ab (Biorad) for 45 min at room 
temperature, washed, and developed using the ECL chemilumi-
nescent detection system (Amersham Biosciences UK Limited, 
Little Chalfont Buckinghamshire, UK). Mouse skin proteins were 
extracted by homogenization in SDS buffer (62.5 mM Tris-HCl 
pH 6.8, 2% SDS, and 10% glycerol). Proteins were separated by 
SDS-PAGE and transferred onto nitrocellulose membranes. Blots 
were blocked with 5% nonfat dry milk in TBS/0.1% Tween 20 
for 1 h, then incubated overnight at 4°C with the primary rab-
bit polyclonal Ab mouse-specific anti-caspase-8 (Cell Signaling 
Technology, Danvers, MA, USA), anti-caspase-3 (Cell Signaling 
Technology), anti-FasL (Abcam, Cambridge, UK), or anti-β-actin 
Ab (AC-15; Sigma). Subsequently, membranes were incubated 
with the appropriate HRP-conjugated secondary Ab (Biorad) and 
developed, as described above. The band intensity was quantita-
tively determined using Image J software.
immunofluorescence
For double cell staining, keratinocyte cultures were washed in 
PBS, fixed in 4% paraformaldehyde for 20  min, and air-dried. 
After rehydration in PBS, cells were permeabilized for 2  min 
with 0.1% Triton X-100, treated for 5 min with 50 mM NH4Cl, 
and incubated with 1% bovine serum albumin for 20 min. Cells 
were then incubated at room temperature for 45 min with mouse 
monoclonal anti-Dsg3 Ab (5H10, Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA) and for 45 min with Alexa Fluor 488 
anti-mouse (Invitrogen). Keratinocytes were washed in PBS/
Tween, labeled with rabbit polyclonal anti-caspase-3 active Ab 
(R&D Systems Inc., Minneapolis, MN, USA) for 45  min and 
with Alexa Fluor 546 anti-rabbit IgG (Invitrogen) for 45 min. For 
visualization of nuclei, 4',6-diamidino-2-phenylindole (DAPI) 
(1 µg/ml, Sigma) was used. Fluorescent specimens were analyzed 
by a Confocal Scanning Laser Microscopy (Leica TCS SP2). 
For mouse-tissue staining, paraffin-embedded tissue sections 
(4 µm) of skin from NIgG and PVIgG-treated mice were paraf-
fin dewaxed, rehydrated, and antigen retrieved (citrate buffer, 
Thermo Fisher Scientific Inc., Fremont, CA, USA). Sections 
were incubated for 1 h with anti-active/cleaved caspase-8 (Novus 
Biologicals, Littleton, CO, USA) and for 45 min with Alexa Fluor 
546 anti-rabbit IgG Ab (Invitrogen). For visualization of nuclei, 
4',6-DAPI (1  µg/ml, Sigma) was used. Fluorescent specimens 
were analyzed by a Confocal Scanning Laser Microscopy (Leica 
TCS SP2).
Dispase-Based Dissociation assay
Normal human keratinocytes were seeded onto 12-well plates, 
cultured, and treated at confluency, as described above. After 
washing with PBS twice, cells were incubated with dispase II 
(>2.4 U/ml; Roche) for 30  min to release cells as monolayers. 
Released monolayers were carefully washed with PBS twice and 
subjected to mechanical stress by pipetting with a 1-ml pipetman. 
Fragments were fixed with 4% formaldehyde and stained with 1% 
Rhodamine B (Sigma). For each single well, the particle number 
was counted and dissociation scores were calculated using the 
number of fragmented cell sheets (N) using the following formula: 
dissociation score = [(N-NNIgG)/(NPVIgG-NNIgG)] × 100.
Measurement of the relative  
acantholytic area
The extent of epidermal acantholysis was measured microscopi-
cally by H&E staining. Samples were analyzed using a conven-
tional optical microscope (Zeiss Axioskope 40). Five random 
microscopic fields per sample were captured at 200× magni-
fication. AxioVision AC imaging software was used to acquire 
sample images. ImageJ software was used to count the number 
of pixels corresponding to the length of each cleft corresponding 
to the areas of the epidermis in which suprabasal cell detachment 
spreads along more than four adjacent basal cells. The percentage 
of the acantholytic area was calculated as the mean of differ-
ent fields. All samples were reported as a ratio against PVIgG 
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treatment or WT animals (in FasL-mutant mice experiments), to 
which a value of 1 was assigned.
caspase assay
Normal human keratinocytes were grown in a multi-96 well black 
plate and treated with FasL (50  ng/ml). The rate of caspase-3 
and -7 activation was measured simultaneously with the fluori-
metric Apo-ONE Homogeneous Caspase-3/7 Assay (Promega 
Corporation, Madison, WI, USA), according to the manufactur-
er’s instructions. Briefly, Apo-ONE Caspase-3/7 reagent mixture, 
containing the profluorescent substrate Z-DEVD-Rhodamine 
110 and lysis/permeabilization buffer, was added to each well, 
gently mixed, and incubated in the dark for 2 h at room tem-
perature. After incubation, the amount of fluorescent product, 
which is proportional to the amount of caspase-3/7 cleavage, was 
measured with a FLUOstar Galaxy fluorimeter (BMG Labtech, 
Germany), using an excitation wavelength of 499  nm and an 
emission of 521 nm. Living cell number was quantified by MTT 
assay in a duplicate transparent plate, by incubating in MTT 
solution (Sigma) for 4 h at 37°C. The formazan dye produced 
after DMSO solubilization was evaluated by a multiwell scanning 
spectrophotometer at 540 nm. The final RFLU/O.D. caspase assay 
results were normalized in relation to MTT values from the same 
experiment.
TUnel assay
Mouse skin samples were fixed in 4% buffered formalin and 
embedded in paraffin. Paraffin sections were processed for 
TUNEL assay using the “In situ cell death detection kit” (Roche 
Diagnostics, Basel, Switzerland), according to the manufacturer’s 
instructions. Briefly, following dewaxing and rehydration, sec-
tions were treated with proteinase K (20 µg/ml; Roche) for 30 min 
at room temperature and incubated with a reaction mixture con-
taining TdT and fluorescence-conjugated dUTP for 1 h at 37°C. 
The labeled DNA was examined by a Confocal Scanning Laser 
Microscopy (Leica TCS SP2 with AOBS).
statistical analysis
Data are presented as mean ± SEM or as ratios with group differ-
ences, obtained from three to five different experiments. Prism 
Software (Graph Pad Software V7.0) was used to perform sta-
tistical analysis. A two-tailed unpaired Student’s t-test was used 
for statistical comparisons between two groups, while one-way 
ANOVA was used for multiple comparisons (as indicated in fig-
ure legends). A value of P < 0.05 or less was assumed to indicate 
a statistically significant difference in the compared parameters.
resUlTs
Fasl induces apoptosis and acantholysis 
in human Keratinocytes
Since PVIgG have been shown to induce the co-aggregation 
of FasL and Fas receptor with caspase-8 in death–inducing-
signaling complex (7), we first analyzed the expression of Fas in 
pemphigus skin. While in normal epidermis, Fas expression is 
confined to the surface of all basal cells, in pemphigus lesions, Fas 
is also found in the suprabasal layers, even before cell detachment 
(Figure 1A). Given that PVIgG upregulate caspase-8 and caspases 
can cleave several adhesion molecules, including Dsgs (18, 19), 
we investigated the effect of recombinant soluble FasL (rFasL) on 
apoptosis and Dsg3. rFasL induces the cleavage of Dsg3 in a dose-
dependent manner (Figure S1 in Supplementary Material) with 
the appearance of a cleaved 80 kD band after 12 h (Figures 1B,C), 
generated by the first degradation of the Dsg3 intracellular tail. In 
addition, rFasL induces the activation of caspase-8 commencing 
at 2 h (Figures 1B,C), followed by the activation of caspase-3/7 at 
4–6 h (Figure 1D). An additional Dsg3 cleavage band at 45 kDa 
is progressively generated (Figures 1B,C), indicating further Dsg 
degradation induced by caspases. By confocal microscopy, cleaved 
(active) caspase-3-expressing cells (red) start to appear from 6 h 
when Dsg expression (green) is still intact. The increase in cleaved 
caspase-3-positive cells is associated with a reduction in Dsg 
expression and a progressive cell-to-cell detachment (Figure 1E, 
arrows). These findings suggest that the final step of the apoptotic 
process (e.g., activation of the executioner caspase-3) occurs in 
the presence of Dsg3 and before cell detachment.
To further evaluate the role of FasL in pemphigus, we per-
formed the cell dissociation assay, a well-established dispase-
based method to measure keratinocyte acantholysis in vitro (20). 
The addition of anti-FasL Ab clearly protects keratinocytes against 
acantholysis induced by PVIgG treatment, in a dose-dependent 
fashion (Figure  2A). Dissociation scoring shows a statistically 
significant reduction of cell sheet fragmentation in the presence 
of anti-FasL (Figure 2B). These data indicate that FasL is relevant 
to cell-to-cell detachment in vitro. In addition, the silencing of 
FasL using siRNA diminishes Dsg3 cleavage and the activation 
of caspase-8 induced by PVIgG (Figures 2C,D). The finding was 
further confirmed by immunofluorescence and indicated that 
blocking FasL by siRNA inhibits Dsg (green) the degradation 
and the activation of caspase-3 (red, Figure 2E). Taken together, 
these findings show that FasL plays a critical role in mediating 
PVIgG-induced apoptosis and acantholysis in vitro.
anti-Fasl ab Blocks Blister  
Formation In Vivo
To confirm the role of FasL in the pathological mechanisms of 
pemphigus in  vivo, we s.c. injected neonatal C57BL/6N mice 
with purified pathogenic PVIgG or NIgG. Twenty hours later, 
the intraepidermal blister and the deposition of autoantibodies 
at the floor and the roof of the cleft (Figure S2A in Supplementary 
Material) recapitulate the immuno-histologic alterations of pem-
phigus in humans. In addition, we detected the activated form 
of caspase-3 in the skin of PVIgG-treated mice but not those 
injected with NIgG, as shown by the appearance of the cleaved 
form of caspase-3 (Figure S2B in Supplementary Material). Our 
findings indicate that PVIgG can activate the apoptotic process 
in vivo. In particular, PVIgG can induce the upregulation of FasL 
protein in mouse epidermis starting at 1 h and caspase-8 activa-
tion at 6 h post injection, respectively (Figure 3A). While blisters, 
as measured by the relative acantholytic areas, were observed at 
12 h (Figure 3B), TUNEL-positive epidermal cells were already 
detected from 9 h after PVIgG treatment (Figure  3C). These 
FigUre 1 | Fas ligand (FasL)-induced apoptosis precedes acantholysis in human keratinocytes: (a) Fas is upregulated in pemphigus skin before cell detachment. 
Cryosections from normal human skin, perilesional, and lesional pemphigus skin were methanol-fixed and stained with anti-Fas antibody (arrows), scale bar: 
100 µm. (B–e) rFasL induces desmoglein (Dsg)3 cleavage through caspases activation in a time-dependent manner. Differentiated keratinocyte monolayers were 
treated with 50 ng/ml of recombinant soluble FasL (rFasL) for different time points. Cell lysates were (B) immunoblotted and (c) protein amounts were quantified 
(means ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001 per Student’s t-test vs cntrl; n = 5 independent experiments). Dsg3 (full), 130 kDa; Dsg3 (cleaved), 80 kDa; 
Dsg3 (second cleavage), 45 kDa. (D) Caspase-3/7 activity was measured at each time point in the presence (+, orange bars) or absence (−, black bars) of rFasL 
(see Materials and Materials). Statistical analysis was performed comparing rFasL-treated samples with its cntrl (−, diluent) at each time point (means ± SEM; 
*P < 0.05; **P < 0.01 per Student’s t-test, compared with diluent; n = 3–5 independent experiments). (e) A representative immunofluorescence image shows Dsg3 
(green) and active caspase-3 (red) expression in keratinocytes treated with rFasL at the indicated time points. Nuclei are shown in blue (4',6-diamidino-2-
phenylindole). Scale bar = 70 µm.
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results demonstrate that pathogenic autoantibodies first induce 
the release of FasL, followed by the appearance of apoptotic epi-
dermal cells, which in turn precedes the onset of blisters in vivo.
To further define the role of FasL in vivo, mice were injected 
with PVIgG alone or in combination with a FasL-blocking Ab 
(40 μg/mouse). Control mice that received PVIgG alone devel-
oped skin lesions 20 h after injection. By contrast, when anti-FasL 
Ab was administered 1 or 2 h after PVIgG injection, blisters were 
still visible but of lesser magnitude. Further, when anti-FasL Ab 
was administered 3 h after PVIgG injection, no blister formation 
was observed (Figure  3D), indicating that blocking FasL pre-
vents acantholysis in vivo. The protective effect of anti-FasL Ab 
against acantholysis was confirmed by measuring the relative 
acantholytic areas in multiple fields from all skin specimens. The 
relative acantholytic area was significantly decreased when anti-
FasL Ab was given 1 h after PVIgG, almost undetectable at 2 h 
and not measurable in mice treated with PVIgG followed by the 
administration of anti-FasL Ab, 3 h later (Figure 3E). Moreover, 
the percentage of TUNEL-positive cells was significantly higher 
in the epidermis from mice treated with PVIgG alone, compared 
FigUre 2 | Keratinocyte-derived Fas ligand (FasL) induces desmoglein (Dsg)3, cleavage, and caspase activation. (a,B) Anti-FasL antibody (Ab) prevents 
keratinocyte acantholysis. Keratinocytes were cultured with purified normal human IgG (NIgG) or pemphigus autoantibodies (PVIgG) in the presence or absence of 
anti-FasL Ab (1 or 15 µg/ml), and dispase-based dissociation assay was performed. (a) Representative images of cell sheet fragmentation. (B) Quantification 
obtained by counting the number of fragments of cell sheets and represented as dissociation score (means ± SEM; **P < 0.01 per one-way ANOVA versus PVIgG; 
n = 5 independent experiments). (c–e) FasL silenced keratinocytes are protected from PVIgG-induced acantholysis and apoptosis. FasL or scrambled siRNA 
transfected keratinocytes were treated with PVIgG or diluent (cntrl), and levels of Dsg3 and caspase-8 were assessed by immunoblot (c) and measured by relative 
protein quantification (D). (e) Immunofluorescence showing Dsg3 (green) and active caspase-3 (red) expression in keratinocytes. Scale bar = 70 µm.
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to mice treated with anti-FasL Ab at 1 or 2 h after PVIgG. No 
TUNEL-positive cells were detected in the epidermis of mice that 
received anti-FasL Ab, 3 h after PVIgG (Figure 3F). Mice were 
subsequently treated with decreasing amounts of anti-FasL Ab 
which inhibited blister formation in a dose-dependent manner, as 
measured by the relative acantholytic area (Figure 3G).
soluble Fasl is required for Blister 
Formation in Pemphigus
To definitely assess the role of FasL in the mechanisms underlying 
pemphigus, we injected PVIgG into two different gene-targeted 
mutant mice that selectively lack either the secreted soluble FasL 
(sFasL), FasLΔs/Δs mice, or the membrane-bound FasL (mFasL), 
FasLΔm/Δm mice (12). Twenty hours after PVIgG treatment, despite 
the deposition of human IgG at the inter-keratinocyte level 
(Figure 4A), no acantholysis was detected in FasLΔs/Δs animals, 
as determined by the histological examination of H&E-stained 
sections (Figure  4B) and the measurement of the relative 
acantholytic areas (Figure 4C). By contrast, blisters were clearly 
visible in PVIgG-treated FasLΔm/Δm animals, lacking mFasL and 
in wild-type (WT) (C57BL/6) mice (Figure  4B). The magni-
tude of the acantholytic areas was significantly decreased (not 
detectable) in FasLΔs/Δs animals, as compared to that in control 
and FasLΔm/Δm mice (Figure 4C). Moreover, TUNEL-positive cells 
were statistically increased only in the skin of PVIgG-treated WT 
and FasLΔm/Δm, but not in FasLΔs/Δs animals (Figure 4D). Finally, 
PVIgG injection failed to induce the activation of caspase-8 only 
in FasLΔs/Δs animals (Figure 4E).
DiscUssiOn
Pemphigus is caused by autoantibodies targeting keratinocyte 
surface antigens. PVIgG binding to these proteins has long been 
considered to directly induce blister formation (21). Yet, it has now 
become clear that additional mechanisms following Ab binding 
contribute to skin blistering in pemphigus. A number of stud-
ies have provided evidence that reduced desmosomal adhesion 
and splitting follow changes in desmosomal structure and Dsg 
depletion (5). Moreover, several signaling pathways downstream 
of Ab binding, including p38 mitogen-activated protein kinase, 
EGFR, c-Myc, etc., have been shown to be involved in the loss 
of keratinocyte adhesion in pemphigus (22). In this context, the 
role of apoptosis has been the subject of much controversy. In 
vitro studies claim that apoptosis is not a prerequisite for skin 
FigUre 3 | Anti-Fas ligand (FasL) antibody (Ab) inhibits blister formation in pemphigus in vivo. (a–c) Neonatal mice were injected with pemphigus autoantibodies 
(PVIgG), sacrificed at various time points, and analyzed for the presence of FasL, acantholysis, and apoptosis activation. (a) FasL protein expression and caspase-8 
activation in mouse skin extracts. (B) Relative acantholytic areas and (c) the percentage of TUNEL-positive cells in mouse skin. Each time point was compared to 0 
h for statistical analysis (means ± SEM; **P < 0.01; ***P < 0.001 per one-way ANOVA; n = 5 animals/each time point). (D–F) Neonatal mice were injected with 
normal human IgG (NIgG) or PVIgG, treated with anti-FasL Ab at the indicated time points and sacrificed at 20 h post PVIgG injection. IgG1κ was used as an isotype 
control for the anti-FasL Ab. (D) Hematoxylin and eosin staining of the neonatal mouse skin. Scale bar = 100 µm. (e) Relative acantholytic areas in mouse skin and 
(F) the percentage of TUNEL-positive cells in mouse skin (means ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001 per Student’s t-test, compared with PVIgG; n = 5 
animals/each treatment). (g) Mice were treated with PVIgG and, 3 h later, with decreasing doses of anti-FasL Ab. Relative acantholysis areas were measured in at 
least three different fields (n = 5 animals/each treatment).
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blistering but can contribute to the acantholytic process (23). By 
contrast, apoptotic cells are detected before blister formation, and 
the inhibition of caspase 3/7 prevents intraepidermal blistering 
in a murine pemphigus model (24). Most importantly, ST18 
overexpression in pemphigus skin (25) confers a significant risk 
for the disease by both upregulating apoptosis and disrupting 
keratinocyte adhesion (26).
Our results clearly indicate a critical role of the Fas/FasL-induced 
extrinsic apoptotic pathway in the pathogenesis of pemphigus, 
consistent with previous studies showing the expression and the 
activation of Fas and FasL in acantholytic cells (7, 8). Specifically, 
we show for the first time that Fas/FasL system is operational before 
blister formation. Upon binding to pemphigus antigens, the Fas/
FasL system leads to the activation of apoptosis and acantholysis. 
Moreover, we provide evidence that apoptosis precedes acantholy-
sis, as Fas overexpression, caspase activation, and the appearance 
of TUNEL-positive cells occur before cell detachment in vivo.
Pemphigus autoantibodies upregulate FasL at the mRNA and 
protein level in human keratinocytes in vitro (14). Here, we report 
that the exposure to PVIgG results in the rapid release of soluble 
FasL in  vivo. Deposits of FasL are present in association with 
intermediate filaments in keratinocytes (13). Because keratins 
control intercellular adhesion (27) and their retraction is associ-
ated with signaling pathways in pemphigus (28), we speculate 
that PVIgG-induced keratin uncoupling from the desmosomal 
complex may contribute to the rapid mobilization and release 
of FasL, resulting in the upregulation of FasL in the intercellular 
milieu. Altogether, our results demonstrate that pathogenic 
autoantibodies first induce the release of FasL, followed by the 
appearance of apoptotic epidermal cells, which in turn precedes 
the onset of blisters in vivo.
The addition of an anti-FasL-neutralizing Ab blocks blister 
formation in mice at 1–3 h after PVIgG injection. This is con-
sistent with the timing of FasL upregulation in the epidermis, 
strongly indicating that anti-FasL blocks its target when it is 
locally released from keratinocytes, upon PVIgG stimulation.
Because mice lacking soluble FasL fail to develop blister 
upon PVIgG injection, we conclude that sFasL is responsible for 
FigUre 4 | Blister formation is blocked in mice selectively lacking soluble Fas ligand (FasL). Wild-type (WT), FasLΔs/Δs, and FasLΔm/Δm mice were each injected with 
either normal human IgG (NIgG) or with pemphigus autoantibodies (PVIgG) and sacrificed at 20 h after injection. FasLΔs/Δs: mice selectively lacking the soluble FasL; 
FasLΔm/Δm: mice selectively lacking the membrane-bound FasL. (a) Representative images of PVIgG binding at the inter-keratinocyte level in the indicated mouse 
strains. Direct immunofluorescence: mouse skin specimens were challenged against fluorescein-conjugated human IgG. EP, Epidermis; D, dermis. Scale 
bar = 100 µm. NIgG (normal IgG) used as a negative control. (B) Representative hematoxylin and eosin staining of mouse skin. Scale bar = 75 µm. (c) Relative 
acantholytic areas in mouse skin (means ± SEM; ***P < 0.001 per one-way ANOVA; n = 10–11 mice/strain). (D) The percentage of TUNEL-positive cells in mouse 
skin treated either with NIgG (green bars) or with PVIgG (orange bars) (means ± SEM; *P < 0.05; ***P < 0.001 per one-way ANOVA; n = 10–11 mice/strain).  
(e) A representative immunofluorescence image showing active caspase-8 (red) expression at the skin level of NIgG or PVIgG-treated mice. Nuclei are shown in blue 
(DAPI). Scale bar = 100 µm.
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acantholysis in  vivo. The data presented here strongly indicate 
sFasL activation of caspase-8 and subsequent activation of 
caspase-3 as the main mechanism accounting for Dsg cleavage 
and blister formation in pemphigus. However, soluble FasL does 
not only trigger the extrinsic apoptotic pathway but also exert a 
number of pro-inflammatory activities (29, 30), which may be 
involved in pathological mechanisms of pemphigus. Whether 
these inflammatory responses could contribute to the develop-
ment of blister remains to be determined.
Previous studies have attempted to prevent blister forma-
tion by pretreating mice with various signal transduction 
inhibitors, before PVIgG injection (31, 32). By contrast, in the 
present study, anti-FasL Ab blocks blister formation by act-
ing after PVIgG injection, thus functioning in a system that 
is closely analogous to human disease. Currently, pemphigus 
therapy consists of the chronic administration of steroids and 
other immunosuppressors, which often results in severe side 
effects with a high fatality incidence. Blocking FasL-induced 
blister formation provides a relevant proof of concept that may 
lead to the development of new drugs to ameliorate pemphi-
gus, possibly replacing the use of broad immunosuppressive 
agents.
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